These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35831856)

  • 21. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.
    Elovaara I; Apostolski S; van Doorn P; Gilhus NE; Hietaharju A; Honkaniemi J; van Schaik IN; Scolding N; Soelberg Sørensen P; Udd B;
    Eur J Neurol; 2008 Sep; 15(9):893-908. PubMed ID: 18796075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
    Eftimov F; Winer JB; Vermeulen M; de Haan R; van Schaik IN
    Cochrane Database Syst Rev; 2013 Dec; (12):CD001797. PubMed ID: 24379104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional outcomes following inpatient rehabilitation of Guillain-Barré syndrome patients: Intravenous immunoglobulins versus plasma exchange.
    Bondi M; Engel-Haber E; Wolff J; Grosman-Rimon L; Bloch A; Zeilig G
    NeuroRehabilitation; 2021; 48(4):543-551. PubMed ID: 34024788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2008 Jan; (1):CD002277. PubMed ID: 18254004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison between IVIg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis of the two treatment modalities.
    Dawson WB; Phillips LH
    Clin Neuropharmacol; 1995 Oct; 18(5):377-90. PubMed ID: 8665552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-minimization analysis in the Indian subcontinent for treating Guillain Barre Syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin.
    Maheshwari A; Sharma RR; Prinja S; Hans R; Modi M; Sharma N; Marwaha N
    J Clin Apher; 2018 Dec; 33(6):631-637. PubMed ID: 30329175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis.
    Barnett C; Wilson G; Barth D; Katzberg HD; Bril V
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):94-7. PubMed ID: 23154126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2012 Jul; (7):CD002063. PubMed ID: 22786476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immunoglobulin treatment of neurological autoimmune diseases.
    Stangel M; Hartung HP; Marx P; Gold R
    J Neurol Sci; 1998 Jan; 153(2):203-14. PubMed ID: 9511879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; Hahn AF; Vermeulen M; Venance SL; van Doorn PA
    J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1331-6. PubMed ID: 25515502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies.
    Dalakas MC
    J Neurol; 2005 May; 252 Suppl 1():I19-25. PubMed ID: 15959668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.
    Soares MO; Welton NJ; Harrison DA; Peura P; Shankar- Hari M; Harvey SE; Madan JJ; Ades AE; Palmer SJ; Rowan KM
    Health Technol Assess; 2012; 16(7):1-186. PubMed ID: 22361003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia.
    Kaur MN; Arnold DM; Heddle NM; Cook RJ; Hsia C; Blostein M; Jamula E; Sholzberg M; Lin Y; Kassis J; Larratt L; Tinmouth A; Carruthers J; Li N; Liu Y; Xie F
    Blood Adv; 2022 Feb; 6(3):785-792. PubMed ID: 34781363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
    Eftimov F; Winer JB; Vermeulen M; de Haan R; van Schaik IN
    Cochrane Database Syst Rev; 2009 Jan; (1):CD001797. PubMed ID: 19160200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
    Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
    Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thromboembolic complications following intravenous immunoglobulin therapy in immune-mediated neurological disorders.
    Chun W; Kim Y; Park SH; Choi SJ
    J Clin Neurosci; 2021 Aug; 90():311-316. PubMed ID: 34275568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective cohort study of plasma exchange in central nervous system demyelinating events in children.
    Manguinao M; Krysko KM; Maddike S; Rutatangwa A; Francisco C; Hart J; Chong J; Graves JS; Waubant E
    Mult Scler Relat Disord; 2019 Oct; 35():50-54. PubMed ID: 31319355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleeding.
    Sruamsiri R; Dilokthornsakul P; Pratoomsoot C; Chaiyakunapruk N
    Pharmacoeconomics; 2014 Aug; 32(8):801-13. PubMed ID: 24849397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies.
    Beauté J; Levy P; Millet V; Debré M; Dudoit Y; Le Mignot L; Tajahmady A; Thomas C; Suarez F; Pellier I; Hermine O; Aladjidi N; Mahlaoui N; Fischer A;
    Clin Exp Immunol; 2010 May; 160(2):240-5. PubMed ID: 20041884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.